Solulin - Haemophilia

Solulin is an improved variant of the human protein thrombomodulin, an important natural regulator of the clotting system. One of the functions of thrombomodulin is to stabilize the initial fibrin clot to stop bleeding. Other than native thrombomodulin which is anchored in the wall of blood vessels, Solulin can enter the blood stream to reach its potential site of action. In low concentrations Solulin is able to stabilise blood clots and to support coagulation. Haemophilia patients could benefit from this property.

According to the WHO about 400,000 people worldwide are currently affected by the hereditary disease haemophilia, including 10,000 in Germany. Therefore, the definition of an “orphan disease” is fulfilled. Solulin has the potential to significantly improve the existing treatment modalities for the patients.

Following the announcement of positive preclinical data PAION has selected haemophilia as the new lead indication for Solulin. In the first half year of 2011 a number of activities were undertaken to substantiate the safety and efficacy profile of Solulin in preclinical and ex vivo studies.

Apart from the positioning in this indication, the possible use of Solulin for the treatment of radiation injury is being further evaluated.